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A B S T R A C T
G-protein coupled receptor (GPCR) mediated activation of the MAPK signalling cascade is a key pathway in the
induction of hypertrophic remodelling of the heart – a response to pathological cues including hypertension and
myocardial infarction. While levels of pro-hypertrophic hormone agonists of GPCRs increase during periods of
greater workload to enhance cardiac output, hypertrophy does not necessarily result. Here we investigated the
relationship between the duration of exposure to the pro-hypertrophic GPCR agonist endothelin-1 (ET-1) and the
induction of hypertrophic remodelling in neonatal rat ventricular myocytes (NRVM) and in the adult rat heart in
vivo. Notably, a 15 min pulse of ET-1 was suﬃcient to induce markers of hypertrophy that were present when
measured at 24 h in vivo and 48 h in vitro. The persistence of ET-1 action was insensitive to ET type A receptor
(ETA receptor) antagonism with BQ123. The extended eﬀects of ET-1 were dependent upon sustained MAPK
signalling and involved persistent transcription. Inhibitors of endocytosis however conferred sensitivity upon the
hypertrophic response to BQ123, suggesting that endocytosis of ETA receptors following ligand binding
preserves their active state by protection against antagonist. Contrastingly, α1 adrenergic-induced hypertrophic
responses required the continued presence of agonist and were sensitive to antagonist. These studies shed new
light on strategies to pharmacologically intervene in the action of diﬀerent pro-hypertrophic mediators.
1. Introduction
Cardiovascular diseases (CVD) are a leading cause of mortality,
accounting for 40% of deaths in males and 49% of deaths in females in
Europe [1]. CVDs comprise a diverse group of pathologies, including
hypertension, myocardial infarction and cardiomyopathy that impact
upon the function of the heart. Through increased resistance of the
vasculature, loss of functional myocardium or poorly functioning
contractile machinery, these conditions elevate the workload on the
heart resulting in hypertrophic remodelling, whereby the heart in-
creases in size without myocyte proliferation [2]. Cardiac remodelling
subsequent to pathological cues, often associated with increased after-
load, is maladaptive. It is characterised by an increase in wall thickness
without an increase in chamber volume (concentric hypertrophy) and is
a prequel to heart failure. At the level of the cardiomyocyte, hyper-
trophy involves enhanced protein synthesis and an increase in sarco-
mere number and organization [3,4]. Cardiac hypertrophy also in-
volves substantial transcriptional remodelling. Most notably, patholo-
gical hypertrophy is characterised by a re-expression of a foetal gene
programme that includes natriuretic peptides, ANF (NPPA) and BNP
(NPPB) and a decrease in expression of the adult α isoform of myosin
heavy chain α-MHC (MYH6) relative to the foetal isoform, β-myosin
heavy chain; β-MHC (MYH7). Physiological hypertrophy however does
not lead to foetal gene programme induction and involves an increase
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in α-MHC (MYH6) relative to β-MHC (MYH7) [4].
While the initial stages of pathological hypertrophy are often
adaptive, continued stress leads to decompensation of the response
culminating in heart failure [3]. Indeed, while chronic application of
the adrenergic agonist dobutamine induces a maladaptive hypertrophic
response, when applied in a pulsatile manner, the hypertrophic
response is adaptive and without ﬁbrosis [5]. A key distinguishing
feature of pathological hypertrophic responses is the primary involve-
ment of Gq-protein coupled receptor (GPCR) signalling [4–7]. GPCR
agonists including endothelin-1 (ET-1) and Angiotensin II (Ang II) are
chronically elevated in disease, including in the myocardium [8,9].
Acting via cognate receptors on cardiac myocytes, they elicit acute
eﬀects on physiology, altering excitation contraction coupling (ECC)
and more chronic eﬀects on cardiac growth through altered transcrip-
tion [10–12]. Pathology-inducing neurohormones may also be elevated
transiently during acute periods of stressful activity such as the ﬁght/
ﬂight response but do not necessarily induce long lasting phenotypic
responses [13,14]. Indeed acutely, epinephrine and norepinephrine
induce immediate chronotropic and inotropic responses, whereas
chronic elevation in the levels of these hormones is required to
stimulate hypertrophic remodelling [13,14].
GPCR activation results in the engagement of multiple downstream
signalling cascades [6]. Notable amongst these in the regulation of
cardiac hypertrophy is the extracellular signal-regulated kinase 1/2
(ERK1/2) MAPK pathway. This signalling cascade plays a central role in
hypertrophy induction through the stimulation of expression and
phosphorylation of immediate early gene (IEG) and activation of
transcription factors such as serum response factor (SRF) and myocyte
enhancer factor-2 (MEF2). Indeed, the expression of the majority of
genes induced following ET-1 is sensitive to MAPK inhibition, indicat-
ing the critical role of this pathway in signalling cardiac remodelling
[15]. ERK1/2 activation is detected within minutes of cell exposure to
agonist or mechanical stretch in vitro [16–18] and within 15 min of
transverse aortic constriction (TAC) in vivo [19,20]. Downstream
consequences of this signalling activity are also detected within minutes
in vitro, as MAPK-stimulated IEG expression is detected within 15 min
of exposure to hypertrophic stimuli [17,18,21]. Consistent with their
role as transcription factors, the induced IEGs stimulate the expression
of multiple downstream targets, including transcription factors, which
then promote the expression of further downstream targets. Indeed,
distinct gene populations are sequentially expressed following ET-1
stimulation in NRVMs [15,21]. This would suggest that, following the
activation of expression of the ﬁrst phase of genes, a cascade is set in
motion that would lead to the induction of subsequent waves of gene
expression [20,22]. While the activity of multiple signalling pathways
required for hypertrophy is rapidly increased proximal to hypertrophic
stimulus, whether the activity of these signalling pathways is also
required for later stages in evolution of the hypertrophic response has
not been determined [10,19,22,23].
While these observations would suggest that sustained signalling
activity is required to elicit the eﬀects of GPCR stimulation, signalling
pathways including MAPK, exhibit rapid and transient increases in their
activity following receptor engagement that peaks in minutes and
decays to baseline within 4 h [15,20]. The maximal induction of IEG
genes also peaks in a relatively short time period of 1 h, after which
their expression decays. The transient nature of these responses is a
product of eﬃcient negative feedback mechanisms that act at multiple
levels downstream of GPCR activation [6].
The rapid, yet transient activation of signalling pathways following
GPCR engagement, relative to the phenotypic outcome of their activa-
tion, raises the question of how these apparently temporally dissociated
processes are coupled. In particular it has not yet been determined
whether the peak signalling activity observed following GPCR engage-
ment is suﬃcient to induce hypertrophy to its full extent, or whether
signalling beyond this initial burst of activity is required [22,23]. A
second elevation in activity of p38 and ERK1/2 7 days after pressure
overload induced by aortic constriction in mice has however been
observed, suggesting that the role of signalling pathways in hypertro-
phy induction goes beyond that proximal to the initial stimulus [20].
Here we tested the hypothesis that sustained activity of signalling
pathways is required for induction of gene expression associated with
pathological hypertrophy. We investigated the time of onset and
duration of signalling activity required for the induction of cardiomyo-
cyte hypertrophy. As a paradigm of hypertrophic signalling, we
focussed at the level of the ETA receptor, its activation of the MAPK
signalling cascade and the myocyte hypertrophic response. Using
primary cultures of ventricular myocytes as a tractable model that
allowed the data sampling required to obtain insights into these early
events, we determined that potent pro-hypertrophic eﬀects of ET-1
(when measured at up to 24 h) are engaged within the ﬁrst 15 min of its
application. Notably, in vivo as in vitro, 15 min infusion of ET-1 was
suﬃcient to elicit a hypertrophic response 24 h later. However,
persistent signalling after 15 min ET-1 application was required for
expression of cellular indices of hypertrophy including increased
protein synthesis and ANF mRNA and protein expression. Notably,
the persistent signalling from ETA receptors was insensitive to antago-
nist in a manner that was modiﬁed by inhibition of endocytosis. These
eﬀects of ETA receptors contrasted with that of the α1 adrenergic
receptor, which required the continued presence of agonist for the
induced-phenotype to be maintained.
2. Materials and methods
2.1. Materials
Chemicals, buﬀers and tissue culture reagents were from Sigma-
Aldrich or Thermo Fisher Scientiﬁc, unless noted otherwise. Sources of
other reagents are speciﬁed.
2.2. NRVM isolation and culture
Animal experiments were performed in accordance with the guide-
lines from the Home Oﬃce code of practice for humane killing of
animals under Schedule 1 of the Animals (Scientiﬁc Procedures) Act
1986 (UK) and in accordance with the European Directive 2010/63/EU
and approved by the Ethical Committee for Animal Experiments of the
KU Leuven (Belgium). Neonatal rat ventricular myocytes (NRVMs) were
isolated from 2 to 3 day old Wistar rats (Charles River) as described
previously [24]. Based on α-actinin staining, NRVM cultures were
deemed> 95% pure. After a pre-plating step to remove adherent non-
myocytes, myocytes were seeded in plating medium (4 parts DMEM
with 4.5 g/l D-glucose, 585 mg/l L-glutamine, 110 mg/l sodium pyr-
uvate and 1 part M199, supplemented with 10% horse serum, 5% foetal
calf serum, 1 mM sodium pyruvate, 1 mM MEM non-essential amino
acids, 1% antibiotic/antimycotic and 3 μM cytosine b-D-arabinofurano-
side; ara-C) either on 1% gelatin-coated dishes or 25 μg/ml laminin-
coated coverslips. Cells were washed and left in plating medium for a
further 24 h. NRVMs were serum-starved in maintenance medium (4
parts DMEM with 4.5 g/l D-glucose, 585 mg/l L-glutamine, 110 mg/l
sodium pyruvate and 1 part M199 supplemented with 1 mM sodium
pyruvate, 1% antibiotic/antimycotic, 3 μM ara-C and 5 ng/ml sodium
selenite) for 24 h before commencing treatments. All agonists and
antagonists and their vehicle controls were diluted in maintenance
media for the durations stated. Where agonists were applied together
with agonist, NRVMs were exposed to antagonist 60 min prior to
agonist addition.
2.3. Cell treatments
ET-1 was from Merck Millipore, prepared as a 200 μM stock in 5%
acetic acid and applied at 100 nM. Phenylephrine (PE) was from Sigma-
Aldrich, prepared as a 10 mM stock in water and applied at 10 μM.
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Inhibitor or vehicle was applied 30 min prior to cell stimulation with
agonist. BQ123 was from Merck Millipore, prepared in water and was
used at 1 μM. Prazosin was from Tocris, prepared in DMSO and was
applied at 100 nM. Dynole (Dynole 34-2) was from Tocris, was
prepared in Ethanol and was applied at 10 μM. PD184352 (PD) was
from Sigma-Aldrich, prepared in DMSO and used at 10 μM.
Actinomycin D (Act D) was from Tocris, prepared in DMSO and applied
at 2 μg/ml. Controls were exposed to vehicle.
2.4. In vivo ET-1 infusion
250–300 g Wistar male rats were obtained from Harlan (NL).
Anesthesia was induced using ketamine and xylazine in combination
(100 mg/kg ketamine, 10 mg/kg xylazine) by intraperitoneal injection.
During anesthesia and throughout the procedure, body temperature
was maintained with a heated mat (Sanitas). After exposure of the
jugular vein, a 30 gauge needle attached to a catheter was introduced.
1 μg/kg of ET-1 was then administered over a 15 min period. This dose
has previously been shown to induce a cardiac eﬀect with minimal
eﬀects on blood pressure [25,26]. For administration, ET-1 was diluted
to 1 ng/μl in saline and infused at a rate of 20 μl/min (total volume
300 μl) using a digital pump dispenser (Harvard). At this rate, acute
vasoconstrictive eﬀect of a single rapid injection of the same dosage are
minimised [27]. Control rats were infused with saline. After the 15 min
infusion, one group of control and ET-1 treated rats were immediately
sacriﬁced by cervical dislocation. For a second group of saline and ET-1
infused rats, the cannula was removed, wound sutured and the animals
allowed to recover for 24 h after which they were sacriﬁced by cervical
dislocation following anesthesia with isoﬂurane. In all cases, hearts
were removed at point of sacriﬁce, rinsed in saline to remove excess
blood and then snap frozen in liquid nitrogen.
2.5. Generation of adenoviral constructs
The GFP adenovirus was as previously described [10]. The GFP-
tagged, dominant negative β-Arrestin-1 (DN β-Arr1) was kindly pro-
vided as cosmid by Prof. Antonio Porcellini (Università degli Studi del
Molise, Italy) [28]. The DN β-Arr1 adenovirus was generated following
transfection into HEK293 cells. After ampliﬁcation in HEK293 cells,
virus was puriﬁed using the Vivapure AdenoPack 100 viral puriﬁcation
kit (Sartorius). Viral titer was determined by end-point dilution and
used at a concentration that transduced> 95% of cells. For infection,
virus was added in a minimal volume of media overlying the cells and
incubated for 3 h. Virus-containing media was then removed and either
replaced with media or media-containing agonist [10].
2.6. Immunoﬂuorescence
NRVMs were washed three times in PBS and then immersed in
ﬁxation buﬀer (2% paraformaldehyde (w/v), 0.05% glutaraldehyde (v/
v) in PBS) at room temperature for 15 min. Cells were washed a further
three times with PBS to ensure removal of ﬁxation buﬀer and
permeabilised in PBS containing 0.2% Triton X-100 for 15 min at room
temperature. After removal of permeabilisation buﬀer, cells were
incubated with blocking buﬀer (0.1% Triton X-100, 5% goat serum in
PBS) for 1 h to block non-speciﬁc protein binding sites. NRVMs were
then exposed to primary antibodies - polyclonal anti-ANF (1:500;
Bachem Cat# T-4014.0400, RRID:AB_518074), mouse monoclonal
anti-α-actinin (1:300; Sigma-Aldrich Cat# A7811, RRID:AB_476766)
or mouse monoclonal anti-β-arrestin1 (1:100; BD Biosciences Cat#
610550, RRID:AB_397907) diluted in blocking buﬀer and incubated for
1 h. Excess antibodies were removed by 4 exchanges of PBS containing
0.1% Triton X-100 over a period of 1 h. Primary Antibodies were
detected with Alexa Fluor® conjugated secondary antibodies (Thermo
Fisher Scientiﬁc), diluted at 1:500 in PBS containing 0.1% Triton X-100
and 2% goat serum, which was left on the cells for 1 h. Cells were then
washed every 15 min for an hour followed by a PBS wash, which was
repeated 3 times. After removal of PBS, cells were mounted by inverting
onto Vectashield mounting medium containing DAPI (Vector labs),
which served to counterstain nuclei. Slides were imaged using an
Olympus FV1000 confocal microscope attached to an Olympus IX81,
equipped with a 40X/1.3 NA UPlanFI oil immersion objective.
Immunolabelling of samples was detected by confocal microscopy
following excitation with laser lines at 405 nm (DAPI, nuclei),
488 nm (Alexa Fluor® 488; α-actinin) and (Alexa Fluor® 568; ANF or
β-arrestin1) 543 nm. For quantiﬁcation of ANF, the percentage of
myocytes with perinuclear ANF in the ﬁeld of view was determined
[10,29]. For each sample, four non-overlapping areas of the cover slips
were counted, which totalled> 350 cells per cover slip enumerated.
2.7. Cell surface area analysis
Cell planimetry was carried out as previously described with some
modiﬁcations [10]. NRVMs plated on gelatin-coated 96 well-dishes and
exposed to conditions described were stained with antibodies against α-
actinin according to the immunoﬂuorescence protocol described above.
After the washes to remove excess secondary antibody, NRVMs were
stained with Hoechst 33342 (Thermo Fisher Scientiﬁc; 10 mg/ml)
diluted in PBS (1:10,000) for 20 min. NRVMs were washed a further
3 times in PBS and left in a ﬁnal volume of 100 μl PBS for imaging. Cells
were imaged using a BD Pathway 855 high-content imaging system.
This system was conﬁgured with an Olympus 40×/0.75 NA UPlan FLN
air objective and a Hamamatsu ORCA ER cooled CCD camera. Caliper
software (BD pathway software) was used for image acquisition,
whereby a 5 × 5 montage of each well of cells was acquired and
speciﬁed using a pre-programmed macro. Cell boundaries were manu-
ally demarcated and area determined using ImageJ software (NIH).
Duplicates of each treatment were analysed with no< 200 cells
measured per condition.
2.8. Protein synthesis measurement by 3H Leucine incorporation
Incorporation of 3H Leucine into newly synthesised proteins is a
robust method to assess the increased protein synthesis associated with
hypertrophy [30]. During the course of treatments with agonists/
inhibitors, 0.5 μCi/ml [3H] Leucine (Perkin Elmer) was added to the
maintenance medium. Following treatments, cells were washed twice
with ice cold PBS. After washing, proteins were precipitated with 5%
trichloroacetic acid (TCA) 1 h on ice. TCA was removed by washing
twice with ice cold PBS and the precipitated proteins were solubilised
by incubating cells with 1 N NaOH for 1 h at room temperature.
Following protein solubilisation, the sample was transferred to scintil-
lation vials containing 5 ml Ultima Gold Scintillation Cocktail (Perkin
Elmer). Tubes were capped, inverted 4 times and then incubated at
room temperature for 10 min to ensure complete mixing. Disintegra-
tions per minute (DPM) were counted for 2 min per sample in a
scintillation counter (Packard Tricarb 4000).
2.9. Quantitative RT-PCR
Total RNA was isolated using Qiazol (Qiagen) or Tri Reagent
(Sigma-Aldrich) followed by chloroform extraction according to the
manufacturer's instructions, with the addition of 1 μl glycogen in the
ﬁnal ethanol wash step as a visible inert carrier of RNA. RNA was
reverse transcribed with Superscript II Reverse Transcriptase (Thermo
Fisher Scientiﬁc). For isolation of RNA from tissue, ~1 mm3 left
ventricle was thawed in TRI Reagent (SIGMA) and then homogenized
using a FastPrep®-24 Instrument and Lysing Matrix D in 2 ml Tubes (MP
Biomedicals). RNA was chloroform-extracted according to manufac-
turer's instruction and isopropanol-precipitated with the addition of
1 μl glycogen in the ﬁnal ethanol wash step as a visible inert carrier of
RNA. 500 ng RNA was used for cDNA synthesis using 0.75 μl
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SuperScript™ II Reverse Transcriptase (Invitrogen) per sample, accord-
ing to the manufacturer's protocol and diluted 1:20 with molecular
biology grade water (Ambion).
Primers for Housekeeping genes and hypertrophic markers spanning
exon boundaries were designed previously [10] (Supplementary Ta-
ble 1). Primers to amplify nascent RNA transcripts were designed
against the intronic regions of Nppa and c-Fos (Supplementary Table 1).
Reactions were performed using Platinum SYBR Green Supermix
(Thermo Fisher Scientiﬁc) or using GoTaq qPCR Mastermix (Promega)
on a Chromo4 Real-time PCR Detector (Bio-Rad) or Light Cycler 480
(Roche). The mean CT values were converted into quantities relative to
the control sample known as the comparative ΔCT method. The indices
for hypertrophy were then normalised to the geometric mean of the
abundance of the 3 most stable housekeeping genes from 14-3-3 protein
zeta/delta (Ywhaz), TATA box binding protein (Tbp), Glyceraldehyde 3-
phosphate dehydrogenase (Gapdh), Troponin T (Tnnt2) and β-2 micro-
globulin (B2m) across the conditions used were selected using the
GeneNorm method [10,31]. For all ﬁgures other than Fig. 6, Gapdh,
Tnnt2 and B2m were used. The quantitation method used generated a
normalised value for the fold change in expression of the hypertrophic
gene marker.
2.10. Immunoblotting
Immunodetection of proteins following SDS-PAGE and western
blotting (immunoblotting) was carried out as previously described,
with minor modiﬁcations [24,32]. NRVMs were scraped into RIPA
buﬀer (10 mM Tris-HCL, pH 7.5, 140 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate, 1×
protease inhibitor cocktail (Sigma-Aldrich), 1× phosphatase inhibitor
cocktail (Sigma-Aldrich), transferred to chilled 1.5 ml tubes and
incubated on ice for 30 min. After this period, cell debris was removed
by centrifugation at 15,000g for 5 min at 4 °C. The protein concentra-
tion of the lysate was determined by BCA assay (Thermo Fisher
Scientiﬁc). 10–20 μg of protein per sample was resolved on a 4–12%
gradient NuPAGE Bis-Tris SDS gel (Thermo Fisher Scientiﬁc). Proteins
were transferred to Immobilon-P PVDF membrane (Merck Millipore) or
0.1 μ nitrocellulose (GE Healthcare) after which non-speciﬁc protein
binding sites were blocked by incubation in Tris-buﬀered saline
containing 0.05% Tween (TBST) and 5% skimmed milk (ECL blocking
buﬀer) for 1 h (detection by enhanced chemiluminescence; ECL detec-
tion) or in TBS blocking buﬀer (Licor) diluted 1:1 in TBS (for Licor-
based detection). For detection of proteins of interest, membranes were
incubated overnight at 4 °C with the required antibodies diluted in
blocking buﬀer (ECL) or TBS blocking buﬀer (Licor) diluted 1:10 in TBS
(for Licor-based detection); mouse monoclonal GAPDH (1:1000; Sigma-
Aldrich Cat# G8795, RRID:AB_1078991), mouse monoclonal phospho
p42/44 MAPK (1:1000; Cell Signaling Technology Cat# 9106S, RRI-
D:AB_331768), rabbit monoclonal phospho p42/44 MAPK (1:1000; Cell
Signaling Technology Cat#4377) mouse monoclonal ERK1 (1:1000; BD
Biosciences Cat# 610031, RRID:AB_397448), mouse monoclonal
ERK1/2 (1:1000, Cell Signaling Technology Cat # 4696) mouse
monoclonal anti-β-arrestin1 (1:500; BD Biosciences Cat# 610550,
RRID:AB_397907). For detection of phosphoproteins by ECL, milk in
the blocking buﬀer was exchanged for 5% bovine serum albumin (BSA).
Antibody binding was detected using horse radish peroxidase (HRP)-
conjugated secondary antibodies (Jackson Immunoresearch) diluted
1:10,000 in blocking buﬀer, which was incubated with the membranes
for 1 h on a rocking platform. Excess secondary antibody was then
removed by 4 washes in TBST over 1 h, followed by a ﬁnal wash with
TBS. Detection of proteins was by Enhanced Chemiluminescence using
Supersignal West Pico Chemiluminescent substrate (Thermo Fisher
Scientiﬁc) and exposure to ﬁlm. For Licor infrared imaging system-
based detection, immunoreactive proteins were detected using IR800
and Alexa680 conjugated secondary antibodies, which were diluted at
1:10,000 in TBST. Immunoreactive bands were quantiﬁed using Image
Studio software (Licor).
2.11. Statistical analysis
Statistical analyses were performed using GraphPad Prism 6. Data
represents a minimum of 3 independent biological replicates, sample
numbers for each experiment indicated in the ﬁgure legend. For testing
statistical signiﬁcance of three or more conditions, the means were
compared by one-way analysis of variance (ANOVA) followed by post-
hoc Holm-Sidak's Multiple Comparison test (for testing statistical
signiﬁcance between groups of the same dataset, illustrated with a line
between groups). A one-sample t-test was used for testing signiﬁcance
between 2 experimental conditions within a data set. Data was taken as
signiﬁcant when p was< 0.05, which was represented as *. p-
Values< 0.01, 0.001, 0.0001 were represented by **, *** and ****,
respectively.
3. Results
3.1. Transient ET-1 exposure upregulated indices of hypertrophy
Primary cultures of NRVMs are an established in vitro model for
analysis of cardiac hypertrophic signalling [33–35]. Exposure of
myocytes to Gq-coupled agonists, including ET-1, for 24 h induces a
cellular hypertrophic response that exhibits features of the in vivo
myocyte hypertrophic response, such as expression of a foetal gene
programme (e.g. Nppa and Nppb; here described as ANF and BNP,
respectively), increased protein synthesis and increased cell size
[10,23,34,35]. The induction of indices of hypertrophy in NRVMs
following exposure to ET-1 (100 nM) for 24 h validated these previous
ﬁndings (Fig. 1). In particular, ET-1 induced increased cell surface area
and protein synthesis (Fig. 1B and C, respectively). Consistent with its
use as a surrogate marker of hypertrophy increased in patients with
cardiac disease and in animal models of hypertrophy [36,37], the
expression of ANF mRNA and protein was also markedly upregulated
following ET-1 exposure (Fig. 1D, Ei and Eii). All of these eﬀects of ET-1
upon NRVMs were inhibited by application of the ETA receptor
antagonist, BQ123 (1 μM), which was applied 60 min prior to and
during ET-1. BQ123 had no aﬀect when applied alone (Fig. 1B–E).
Having shown the pro-hypertrophic eﬀect of ET-1 and its sensitivity
to BQ123, we set out to determine the minimum duration of ET-1
exposure required to induce the hypertrophic phenotype observed at
24 h. ET-1 was applied to NRVMs for 15 or 30 min, at which time it was
removed by 2 washes with fresh medium and BQ123 added to prevent
further signalling from the ETA receptor (Fig. 2A). NRVMs were
harvested for analysis 24 h from the point of agonist addition. An
increase in general protein synthesis and of ANF mRNA and protein
expression was observed for each of the ET-1 exposure times analysed
(Fig. 2B, C and D, respectively). An increase in BNP mRNA, which is
also typically observed in the hypertrophic response [38], was detected
in NRVMs exposed to ET-1 for 15 or 30 min (Supplementary Fig. 1).
Notably, the magnitude of hypertrophic response (measured at 24 h)
was no diﬀerent between NRVMs exposed to ET-1 for 15 min or 24 h.
To further probe the persistence of the eﬀect of 30 min exposure to
ET-1 upon the hypertrophic response and to gain closer insight into the
longer time scales over which hypertrophy is induced in vivo, the time
point for measurement of hypertrophy following the 30 min exposure to
ET-1 and its replacement with BQ123 was extended to 48 h (Fig. 3).
Under these conditions, the hypertrophic response was maintained up
until the 48 h time point, with no diminution of the magnitude of the
response observed when compared to that measured at 24 h. In
addition, upregulation of ANF mRNA expression was sustained when
ET-1 was incubated for 24 h and assayed 12 and 24 h later (Supple-
mentary Fig. 2).
To investigate whether the persistence of hypertrophic signalling
was speciﬁc to the ET-1/ETA receptor activation cascade or was a more
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general feature of hypertrophic responses to Gq agonists, the hyper-
trophic response to the Gq coupled α1 adrenergic receptor agonist PE,
was analysed [18,35]. To avoid possible inﬂuence of paracrine/auto-
crine signalling by ET-1 reported in NRVMs undergoing hypertrophy
[10], BQ123 was applied to cells following removal of PE. As observed
for ET-1, exposure of NRVMs to PE for 15 min (10 μM) was suﬃcient to
induce expression of hypertrophy indices 24 h later (Fig. 4A, B and C).
Application of BQ123 subsequent to the addition of PE to inhibit the
potential activation of ETA receptors did not aﬀect PE-induction of
hypertrophy, ruling out their contribution to signalling cascades
activated by PE. In contrast, despite also acting through a GPCR
pathway involving Gq, application of the α1 adrenergic receptor
antagonist Prazosin (100 nM) 15 min post PE application abrogated
its pro-hypertrophic action [35]. Prazosin also inhibited the induction
of hypertrophic markers when applied prior to PE addition (Fig. 4D).
The contrasting eﬀects of inhibition of ETA and α1 adrenergic receptors
subsequent to 15 min exposure of their cognate ligand, would suggest
diﬀerent signalling mechanisms for these receptors. In particular, that
continuous ligand association is required for α1 adrenergic receptor-
mediated induction of hypertrophic gene expression, whereas, ET-1
elicits its pro-hypertrophic eﬀects within 15 min of application.
3.2. Persistence of the pro-hypertrophic eﬀect of ET-1 requires sustained
transcription post agonist removal
The presence of a hypertrophic response at 24 h, despite removal of
ET-1 and application of BQ123 15 min after ET-1 addition, raised the
question whether transcription of hypertrophy-related marker genes
and protein synthesis observed at 24 h was induced within this initial
stimulation time period. Levels of ANF mRNA and protein synthesis
were therefore measured at 15 and 30 min subsequent to agonist
application. When assayed at these time points, no induction in ANF
Fig. 1. Stimulation of NRVMs with ET-1 for 24 h induces upregulation of hypertrophic markers. A. Cartoon illustrating the experimental protocol and time course of ET-1 and BQ123
application. Cells were harvested and assays were performed at 24 h after agonist addition. B. Box plots showing cell surface area measurements of NRVMs exposed to ET-1 ± BQ123 for
24 h. Box spans the 25th and 75th percentile, the line marks the median and the whiskers mark the minimum and maximum data points from at 3 primary cell preparations (n≥ 30 cells
per group, ****p < 0.0001). C. 3H leucine incorporation assay of protein synthesis showing fold change relative to the control upon stimulation with ET-1 ± BQ123. Each bar
represents the mean ± SEM (n = 4 primary cell preparations, *p < 0.05, ****p < 0.0001). D qRT-PCR analysis of ANF mRNA abundance relative to the control upon stimulation with
ET-1 ± BQ123. Each bar represents the mean ± SEM (n = 3 primary cell preparations, *p < 0.05, **p < 0.01). Ei. Representative confocal images of NRVMs exposed to ET-
1 ± BQ123 for 24 h and immunostained for ANF in red, α-actinin in green and nuclei in blue (DAPI). Scale bar represents 50 μm. Peri-nuclear rings of ANF in red are indicated with a
white arrow. Eii. Percentage of NRVMs treated with ET-1 ± BQ123 exhibiting a peri-nuclear ring of ANF. Box spans the 25th and 75th percentile, the line marks the median and the
whiskers mark the minimum and maximum data points from 4 primary cell preparations (*p < 0.05, ***p < 0.001). Statistical analysis was performed using a one-way ANOVA
followed by post-hoc Holm-Sidak's Multiple Comparison test (symbols above bars/plots). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)
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mRNA or protein synthesis was observed (Supplementary Fig. 3Ai and
B), whereas, consistent with experiments above, ANF mRNA and
general protein synthesis were both elevated when measured 24 h post
agonist application. Having observed no induction of ANF mRNA at
30 min, we also performed a more detailed analysis of ANF mRNA
expression between from 1 h and 24 h post agonist application. This
analysis revealed an induction of expression of ANF mRNA at 1 h that
did not substantially alter throughout the time course of the experi-
ment, suggesting that peak expression was reached (Supplementary
Fig. 3Aii). To determine whether exposure to ET-1 for< 30 min was
suﬃcient to elicit a transcriptional response in our experimental model
and to control for detection of a response, the induction of the IEG c-Fos
was also quantitated. Induction of IEG expression is a primary
transcriptional response to mitogenic agonists, including GPCRs en-
gagement in NRVMs [39]. As IEGs act as transcription factors, induc-
tion of IEG expression represents an initial step in the pathway to more
wholesale transcriptional regulation [39]. Notably, while the induction
of indices of hypertrophy were not detected within 30 min post agonist
application, ET-1 application promoted a substantial increase in c-Fos
mRNA by 15 min that peaked at 30 min and then declined after 1 h to
an elevated plateau for the remainder of the experimental time course
(Supplementary Fig. 3C). This expression proﬁle contrasted with that
observed for ANF mRNA, which upon eliciting its response to ET-1,
remained at a similar level for the duration of the experimental time-
course (Fig. 2 and Supplementary Fig. 3A).
To further understand the mechanism by which hypertrophy was
induced at 24 h following exposure to ET-1 for 15 min, yet absent when
measured at 15 or 30 min, we tested whether the hypertrophic response
at 24 h and later time points was mediated by the persistence of active
transcription beyond this period of agonist exposure or was due to
transcripts generated during the initial stimulation period. The require-
ment for persistent transcription after removal of agonist at 15, or
30 min for the hypertrophic response measured at 24 h was probed by
analysing the eﬀect of inhibition of transcript elongation by RNA
polymerase II with Actinomycin D (Act D) (2 μg/ml) at the point of
agonist removal [40]. As previously, ET-1 was applied to NRVMs for 15
or 30 min. At these time points, Act D or vehicle control was added in
the continued presence of the hypertrophic agonist. At 24 h, the cells
were assayed for ANF mRNA expression or protein synthesis. Addition
of Act D 15 or 30 min post ET-1 addition inhibited the induction of ANF
mRNA expression and protein synthesis normally observed (Fig. 5A and
B, respectively). Since hypertrophic transcripts were not observed at the
time points of Act D addition (15 and 30 min after ET-1; Supplementary
Fig. 3A), the absence of these transcripts and hypertrophy at 24 h
indicates that they are produced as a result of persistent transcription.
To establish whether ANF mRNA quantitated at the 24 and 48 h
time points following brief agonist exposure resulted from persistent
active transcription up until the point of cell harvesting, the abundance
of nascent ANF transcripts at this time point was measured. Given that
RNA splicing occurs concomitant with transcription [21], the analysis
of nascent transcripts reﬂect transcriptional activity. Agonist was
applied, after 15 or 30 min removed and replaced with BQ123. As for
mRNA analysis, cells were harvested 24 h after the addition of agonist.
A control in which agonist was applied for 24 h was also included in the
analysis. Increased abundance of nascent transcripts for ANF was
detected at 24 h for all conditions tested (Fig. 5C). Moreover, nascent
transcripts were detected up to 48 h following a 30 min exposure to ET-
1 (Fig. 5D). These ﬁndings are analogous to that observed for expres-
sion of the mature ANF transcript following ET-1 application. These
data indicate that transient agonist exposure sets in motion mechanisms
Fig. 2. ET-1 application for 15 min with ETA receptor antagonism upon removal upregulates hypertrophic markers in NRVMs when measured at 24 h. A. Cartoon illustrating the
experimental protocol and time course of ET-1 and BQ123 application. Cells were harvested and assays were performed at 24 h after agonist addition. B. 3H leucine incorporation assay of
protein synthesis showing fold change relative to the control upon stimulation with ET-1 ± BQ123. Each bar represents the mean ± SEM (n = 3 primary cell preparations, *p < 0.05,
**p < 0.01, ****p < 0.0001, NS; not signiﬁcant). C. qRT-PCR analysis of ANF mRNA abundance relative to the control upon stimulation with ET-1 ± BQ123. Each bar represents the
mean ± SEM (n = 4 primary cell preparations, *p < 0.05, **p < 0.01, ***p < 0.001, NS; not signiﬁcant). D. Percentage of NRVMs treated with ET-1 ± BQ123 exhibiting a peri-
nuclear ring of ANF. Box spans the 25th and 75th percentile, the line marks the median and the whiskers mark the minimum and maximum data points from 8 primary cell preparations
(*p < 0.05, **p < 0.01, ****p < 0.0001, NS; not signiﬁcant). Statistical analysis was performed using a one-way ANOVA followed by post-hoc Holm-Sidak's Multiple Comparison test
(symbols above bars/plots).
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to induce persistent activation of the transcription machinery involved
in transcribing ANF.
3.3. 15 minute ET-1 exposure induces hypertrophy-associated transcripts at
24 h in vivo
To test the physiological relevance of our observations, the capacity
for a brief exposure of ET-1 to have persistent eﬀects on hypertrophy-
associated gene expression was tested in vivo. ET-1 was infused in rats
via the jugular vein over a 15 min time period. A dose of ET-1 was
applied that has previously been shown to cause eﬀects on cardiac
physiology without substantial changes in blood pressure [25,26].
Hearts were then either harvested at this point or 24 h later after
cessation of the 15 min infusion and recovery of the rats (Fig. 6A).
Analysis of gene expression in these hearts was then performed. At the
15 min time point, no change in expression of ANF or BNP was
detected, whereas at 24 h, expression of these markers of hypertrophy
was observed (Fig. 6B and D). Moreover, the nascent mRNA for these
hypertrophic markers was also increased at 24 h, indicating sustained
transcription (Fig. 6C and E). Contrastingly, 15 min was suﬃcient to
elicit an increase in expression of c-Fos, which was sustained, albeit at a
signiﬁcantly lower level until 24 h (Fig. 6F). Nascent transcripts for c-
Fos were also elevated at 24 h, suggestive of continued basal activity of
the IEG response (Fig. 6G). These in vivo data are consistent with our
observations in vitro and show relevance of our ﬁndings to the pro-
hypertrophic eﬀects of ET-1 in vivo. While we did not apply an inhibitor
of the ETA receptor in vivo, at the dose applied, venous levels of ET-1
measured 15 min subsequent to cessation of ET-1 infusion were
previously shown to be no diﬀerent from saline -infused controls
[25]. Moreover, ET-1 is cleared from the circulation very rapidly in
an ETB receptor dependent manner with a t1/2 of 18 s [41]. The eﬀects
of ET-1 observed at 24 h are thus not due to sustained elevated levels in
the circulation.
3.4. MAPK activity downstream of ET-1 is required for induction of
hypertrophic gene expression
The data presented above (Fig. 2) indicate that a brief exposure to
ET-1 is suﬃcient to induce hypertrophic indices and IEG expression
measured at 24 h despite removal after 15 min and antagonist applica-
tion. However, measures of hypertrophy were not induced at the point
of agonist removal (Supplementary Fig. 3A and B). Given the central
role of the ERK1/2 MAPK pathway in the IEG response and pro-
hypertrophic action of ET-1 [6,21], its involvement in the hypertrophic
remodelling observed was measured. NRVMs were stimulated with ET-
1 for 5, 10, 30, 60 min and 24 h, and levels of active phosphorylated
ERK (pERK1/2) assessed. As previously described, a low level of
phosphorylated active ERK1/2 (pERK1/2) was detected under baseline
conditions [18]. Consistent with previous reports, ET-1 application
resulted in a rapid and substantial increase in pERK1/2 levels by 5 min
[18], that remained elevated before returning to baseline after the 1 h
time point (Fig. 7A). No change in expression of total ERK was detected
over this time course. ERK1/2 phosphorylation remained at basal levels
at 3 and 12 h suggesting no additional wave of ERK activation
(Supplementary Fig. 4). To dissect the time window where the activity
of this pathway was required to drive ET-1-induced hypertrophic
signalling, ERK activity was inhibited at relevant time points post ET-
1 addition. To this end, the direct upstream kinase of ERK1/2, MEK1/2
was inhibited with PD184352 (PD; 10 μM), which is a highly eﬀective
in speciﬁcally suppressing ERK1/2 activity [42]. Consistent with the
necessity of MEK for ERK1/2 activation, PD inhibited the ET-1
stimulated increase in pERK1/2 in NRVMs (Fig. 7B). PD application
at 15 or 30 min subsequent to addition of ET-1 prevented the
upregulation of ANF mRNA and protein synthesis observed at 24 h
(Fig. 7C and D, respectively). These data indicate that ERK1/2 activity
beyond the 30 min exposure to ET-1 is necessary for hypertrophy
induction at 24 h. Together, these data, generated in experiments in
which inhibitors are applied at 15 or 30 min after ET-1 (Act D inhibition
of transcription, the presence of nascent IEG and ANF nascent
transcripts and PD inhibition of MAPK signalling), strongly support
the conclusion that the ET-1-liganded ETA receptor elicits persistent
signals (beyond duration of ET-1 exposure) that are required for the
hypertrophic response at 24 h.
3.5. Inhibition of endocytosis mechanisms potentiates induction of markers
of hypertrophy induced by brief exposure to ET-1
The hypertrophic response observed at up to 48 h, following a
stimulus lasting only 15 min, insensitive to subsequent ETA receptor
antagonist, yet requiring downstream signalling after the period of
agonist exposure, is suggestive of a mechanism in which the active ETA
receptor becomes insulated from antagonist following ligand binding.
Subsequent to ligand association, GPCRs undergo inactivation through
phosphorylation or internalisation via an arrestin/clathrin-dependent
mechanism. Despite internalisation, ligand-bound ET receptors have
been reported to continue to signal from an intracellular location [43].
To determine whether ETA receptor endocytosis underlies the insensi-
tivity of ET-1 action to BQ123, endocytosis was inhibited and eﬀects
analysed. To this end, complementary approaches involving genetic
and a pharmacological intervention of receptor endocytosis was
employed. Given that ETA receptor internalisation occurs through an
arrestin/clathrin-dependent mechanism, a dominant negative form of
β-Arrestin 1 (DN β-Arr1) was overexpressed to suppress this pathway
[44]. The DN β-Arr1 employed harbours a V53D mutation, which has
an enhanced aﬃnity for clathrin and impaired interaction with GPCRs
due to the presence of the mutation in the primary GPCR binding
domain [45,46]. Overexpression of DN β-Arr1 was achieved using
adenovirus, which also mediated expression of GFP under a separate
promoter, thereby allowing identiﬁcation of transduced cells. Trans-
duction of NRVMs with the DN β-Arr1 adenovirus for 8 h resulted in
Fig. 3. ET-1 application for 30 min with ETA receptor antagonism upon removal
upregulates hypertrophic markers in NRVMs when measured over a prolonged time-
course for up to 48 h.i. Cartoon illustrating the experimental protocol and time course of
ET-1 and BQ123 application. Assays were performed at 24 or 48 h. ii. qRT-PCR analysis of
ANF mRNA abundance relative to the control upon stimulation with ET-1 for 30 min
+ BQ123 at 24 or 48 h. Each bar represents the mean ± SEM (n = 3 primary cell
preparations, *p < 0.05, **p < 0.01). Statistical analysis performed using the one-way
ANOVA followed by post-hoc Holm-Sidak's Multiple Comparison (symbols above bars/
plots).
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expression of DN β-Arr1 and GFP, which were detected by immuno-
blotting and confocal imaging respectively (Fig. 8A and B). NRVMs
transduced with an adenovirus encoding GFP alone exhibited GFP
expression but no increase in β-Arr1 immunoreactivity. DN β-Arr1
expression was detected in the majority of NRVMs transduced with the
DN β-Arr1 adenovirus and coincided with GFP expression from the
same virus (Fig. 8B). Immunoblot analysis of lysates prepared from DN
β-Arr1 transduced cells revealed a signiﬁcant increase in β-Arr1
expression relative to GAPDH (Fig. 8A). The eﬀect of DN β-Arr1
expression on ET-1-stimulated increase in ANF mRNA was next
determined. In these analyses, NRVMs were infected with the DN β-
Arr1 adenovirus 24 h in advance of agonist application. NRVMs were
stimulated for 15 min with ET-1 after which the agonist was washed oﬀ
and replaced with BQ123. NRVMs were harvested 24 h later. ANF
mRNA abundance (measured at 24 h) was increased following ET-1
application for 15 min in NRVMs infected with control GFP and DN β-
Arr1 adenoviruses (Fig. 8C). The magnitude of the increase in ANF
mRNA was however signiﬁcantly greater in myocytes transduced with
DN β-Arr1 adenovirus compared to myocytes transduced with the GFP
control virus. More signiﬁcantly, the presence of DN β-Arr1 resulted in
acquisition of sensitivity of the ET-1 induced increase in ANF mRNA to
BQ123. Speciﬁcally, the ET-1 stimulated increase in ANF mRNA at 24 h
was signiﬁcantly blunted in DN β-Arr1 transduced cells in which ET-1
was applied for 15 min and then replaced after 15 min with BQ123.
Consistent with that observed for non-infected NRVMs, BQ1213 did not
suppress the ET-1 stimulated induction of ANF mRNA in myocytes
transduced with GFP adenovirus (Fig. 8C).
The role of receptor endocytosis in ET-1 stimulated hypertrophy
was examined further by inhibition of the GTPase activity of dynamin II
with Dynole 34-2 (10 μM) [47]. Dynamin is a GTPase, which plays a
central role in clathrin-mediated endocytosis, a process involved in the
desensitisation of plasma membrane receptors, including ETA receptors
[44,48] in many cells types, including myocytes [49]. Dynole 34-2 was
applied to NRVMs following 15 min stimulation with ET-1. Consistent
with results obtained by DN β-Arr1 expressing myocytes, Dynole 34-2
addition following exposure to ET-1 for 15 min rendered the ET-1
stimulated increase in ANF mRNA sensitive to BQ123 as well as
augmenting the ET-1 stimulated increase in ANF mRNA (Fig. 8D).
The potentiation of the ANF response to ET-1 and its endowment
with BQ123 sensitivity supports a model in which through preventing
endocytosis, DN-β-Arr1 expression or dynamin inhibition serves to
maintain ETA receptor at the sarcolemma, where its activation by ET-1
is enhanced and its inhibition by BQ123 increased (Fig. 8E).
Taken together with prior evidence from the literature, the data
presented above suggest a model by which ET-1 promotes ETA receptor
activation of downstream signalling and receptor endocytosis
[44,48,50,51]. From this intracellular location, liganded ETA receptor
signalling persists through a ligand trapping mechanism to sustain the
eﬀects of agonist exposure.
4. Discussion
Our ﬁndings provide new insights into the mechanism by which ET-
1 signals via its receptor to induce hypertrophic gene expression. Our
results show that the pro-hypertrophic eﬀects of ET-1 are engaged
within minutes, but endure for longer than 48 h in a manner insensitive
Fig. 4. PE application for 15 min with ETA receptor or α1-adrenergic receptor antagonism upon removal upregulates hypertrophic markers in NRVMs when measured at 24 h. A. qRT-PCR
showing fold change in ANF mRNA expression relative to the control upon stimulation with PE ± BQ123. Assays were performed at 24 h. Each bar represents the mean ± SEM (n = 5
primary cell preparations, **p < 0.01, ***p < 0.001, ****p < 0.0001, NS; not signiﬁcant). B. 3H leucine incorporation assay of protein synthesis showing fold change relative to the
control upon stimulation with PE ± BQ123. Each bar represents the mean ± SEM (n = 4 primary cell preparations, *p < 0.05, **p < 0.01, ***p < 0.001, NS; not signiﬁcant). C.
Percentage of NRVMs treated with PE ± BQ123 exhibiting a peri-nuclear ring of ANF. Box spans the 25th and 75th percentile, the line marks the median and the whiskers mark the
minimum and maximum data points from 3 primary cell preparations (****p < 0.0001, NS; not signiﬁcant). D. qRT-PCR analysis of ANF mRNA abundance relative to the control upon
stimulation with PE ± Prazosin. Assays were performed at 24 h. Each bar represents the mean ± SEM (n = 4 primary cell preparations, **p < 0.01, ***p < 0.001). Statistical
analysis was performed using a one-way ANOVA followed by post-hoc Holm-Sidak's Multiple Comparison test (symbols above bars/plots).
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to ET-1 removal and ETA receptor antagonism. Notably, the persistent
eﬀect of ET-1 was conserved in vivo. This property of ET-1/ETA receptor
signalling contrasted with signalling from the α1 adrenergic receptor,
which was entirely sensitive to antagonist. The persistent hypertrophic
eﬀects of ET-1 required the sustained activity of the MAPK pathway
downstream of the ETA receptor. Inhibition of classical receptor
endocytic pathways rendered myocytes transiently exposed to ET-1
sensitive to ETA receptor antagonism. This suggested that the sustained
and antagonist-insensitive action of ET-1 involves a mechanism in
which following ET-1 association, the ET-1/ETA receptor complexes is
internalised and continues to signal due to insulation from receptor
antagonism.
GPCR signalling evokes both acute and long-term eﬀects in the heart
as adaptive responses to increased workload/stress. Acutely, changes in
physiology are observed that mediate enhanced cardiac function,
whereas chronically, a hypertrophic growth response of the myocytes
of the heart occurs. When associated with prolonged stress, hyper-
trophic cardiac growth predisposes to cardiac decompensation and
failure [3]. However, the initial stages of the hypertrophic response are
detectable within hours [21]. This apparent sensitivity of the heart to
the demands of the organism must also be balanced by mechanisms to
ensure that the hypertrophic response and the deleterious eﬀects of
cardiac function associated with it are not erroneously activated by
acute stressors, for example during periods of physiologically-increased
sympathetic innervation [52]. As GPCR signalling is key to pathological
cardiac remodelling [6], we analysed how the activity of a key
downstream pathway – the ERK1/2 MAPK cascade - is coupled to the
hypertrophic response induced by ET-1. ET-1 is a potent pro-hyper-
trophic agonist that elicits acute eﬀects on cardiac physiology as well as
longer term eﬀects by inducing pathological cardiac hypertrophic
growth [10,21,53,54]. These actions of ET-1 have been extensively
modelled in vitro in primary cultures of cardiac myocytes. This model
has proven a highly tractable and physiologically relevant test-bed to
delineate signalling pathways and their contribution to cellular remo-
delling downstream of the ETA receptor [10,21,33]. Despite being
necessary and suﬃcient for the induction of pathological remodelling of
the heart in vivo, the role of ERK1/2 in cardiac hypertrophy is
complicated. In particular, while ERK is required to prevent eccentric
cardiac growth, an increase in its activity induces pathological growth
[55–57]. Numerous studies have also demonstrated the requirement for
MAPK signalling (ERK1/2) in regulating hypertrophic remodelling in
vitro [6,7,10]. The involvement of ERK1/2 signalling in the transcrip-
tional responses underlying the pro-hypertrophic eﬀects of ET-1 was
recently demonstrated by the substantial eﬀects of MAPK inhibition
upon ET-1 stimulated changes in the neonatal myocyte transcriptome.
These studies revealed that the expression of the majority of genes
upregulated in ET-1 stimulated myocytes was dependent on the ERK1/2
cascade [15]. Consistent with these analyses, we observed a potent
eﬀect on myocyte hypertrophy and the foetal gene expression pro-
gramme in myocytes exposed to ET-1 for 24 h. Surprisingly however,
ET-1 exhibited similar eﬀects on indices of myocyte hypertrophy when
applied for only 30 min and replaced after this initial exposure with ETA
receptor antagonist. These eﬀects contrasted with that of the α1
adrenergic receptor agonist PE, which induced expression of markers
of hypertrophy that were sensitive to agonist wash oﬀ and receptor
antagonism (with prazosin). A similar antagonism of PE eﬀects on
hypertrophic remodelling in NRVMs has recently been described.
However, while in the work presented here prazosin prevented a
hypertrophic response before it had developed, in the study described,
it reversed hypertrophy that had developed over 24 h [35]. While the
ability of ET-1 to elicit such long lasting eﬀects is surprising, the
sustained action of ET-1, together with its high aﬃnity for its receptor,
contributes to its potency as a pro-hypertrophic agonist and provides a
mechanism by which it can act at nanomolar levels in the circulation. In
Fig. 5. Persistence of ANF following removal of ET-1 is due to its continued active transcription. A. qRT-PCR analysis of ANF mRNA abundance relative to the control upon stimulation
with ET-1 ± Act D. Assays were performed at 24 h. Each bar represents the mean ± SEM (n = 4 primary cell preparations, *p < 0.05). B. 3H leucine incorporation assay of protein
synthesis showing fold change in protein synthesis relative to the control upon stimulation with ET-1 ± ActD. Assays were performed at 24 h. Each bar represents the mean ± SEM
(n = 7 primary cell preparations, **p < 0.01, ***p < 0.001). C. qRT-PCR analysis of ANF nascent mRNA abundance relative to the control upon stimulation with ET-1 + BQ123.
Assays were performed at 24 h. Each bar represents the mean ± SEM (n = 4 primary cell preparations, **p < 0.01). D. qRT-PCR analysis of ANF nascent mRNA abundance relative to
the control upon stimulation with ET-1 + BQ123 at 24 or 48 h. Each bar represents the mean ± SEM (n = 3 primary cell preparations, *p < 0.05, **p < 0.01). Statistical analysis was
performed using a one-way ANOVA followed by a post-hoc Holm-Sidak's Multiple Comparison test (symbols above bars/plots).
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addition to being synthesised by endothelial cells of the vasculature,
ET-1 is also produced by cardiac myocytes allowing it to act in an
autocrine/paracrine manner [10,58]. Indeed, ET-1 is elevated in the
myocardium during disease and increased in vitro in response to pro-
hypertrophic stimulation [8,58].
To explain the long lasting eﬀects of ET-1, we ﬁrst considered the
possibility that the GPCR-proximal downstream signals set in motion a
feed forward mechanism by which the initial products of signalling
drive subsequent pro-hypertrophic mediators, in a manner independent
of the presence of the initiating stimulus. In this way, the cell retains a
memory of its exposure to agonist. We considered that this ‘memory’
was achieved through either, or both sustained alteration in signalling
or reprogramming of cell transcription [59,60]. These mechanisms may
also determine the nature of reversibility of the response downstream of
Fig. 6. A 15 min ET-1 infusion induces hypertrophy-associated transcripts at 24 h in vivo. A. Cartoon illustrating the in vivo experimental protocol and time course of vehicle (saline) and
ET-1 infusion. Vehicle control rats were infused with saline. After the 15 min infusion, one group of vehicle and ET-1 treated rats were immediately sacriﬁced (top bars; sample collection
indicated with arrows). For a second group of vehicle and ET-1 infused rats, the animals were allowed to recover for 24 h before sacriﬁce (lower bars; sample collection indicated with
arrows). B–E. Analysis of nascent and mature transcripts of IEGs and hypertrophy markers ANF and BNP mRNA in heart tissue from animals infused with ET-1 or saline according to the
protocol in A. B. qRT-PCR analysis of ANF mRNA abundance. Each bar represents the mean ± SEM (n = a minimum of 6 rats for each treatment, ****p < 0.0001, NS; not signiﬁcant).
C. qRT-PCR analysis of nascent ANF mRNA. Each bar represents the mean ± SEM (n = a minimum of 6 rats for each treatment, ***p < 0.001, NS; not signiﬁcant). D. qRT-PCR analysis
of BNP mRNA abundance. Each bar represents the mean ± SEM (n = a minimum of 6 rats for each treatment). E. qRT-PCR analysis of nascent BNP mRNA abundance. Each bar
represents the mean ± SEM (n = a minimum of 6 rats for each treatment) F. qRT-PCR analysis of c-Fos mRNA abundance. Each bar represents the mean ± SEM (n = a minimum of 6
rats for each treatment, ****p < 0.0001, NS; not signiﬁcant) G. qRT-PCR analysis of nascent c-FosmRNA abundance. Each bar represents the mean ± SEM (n = a minimum of 6 rats for
each treatment, ****p < 0.0001, NS; not signiﬁcant) Statistical analysis was performed using a one-way ANOVA followed by a post-hoc Holm-Sidak's Multiple Comparison test (symbols
above bars/plots).
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the initiating signal. These eﬀects are exempliﬁed by the ERK/MAPK
signalling pathway, in which diﬀerential activation of ERK cascades,
either sustained or transient, generate distinct cellular outcomes [61].
Moreover, and in support of this idea, ET-1 stimulates the expression of
temporally distinct functional classes of genes in NRVMs [21]. For
example, IEG are ﬁrst apparent, followed by signalling and then
structural genes. The requirement for IEG expression and activity for
later transcriptional events has been described [62]. Consistent with
this model, expression of the IEG c-Fos was rapidly induced following
ET-1 stimulation (< 15 min), while expression of classical markers of
hypertrophy developed later. Demonstrating the physiological impor-
tance of our ﬁndings, these eﬀects of ET-1 observed in the NRVM model
were conserved in an in vivo model in which ET-1 was infused via the
jugular vein. Following their induction, despite only a 30 min exposure
of cells to agonist, levels of hypertrophy-associated targets remained
elevated for 48 h, and surprisingly at a level similar to that observed in
cells exposed to agonist for the full duration of the experiment. Through
combining the inhibition of transcriptional elongation and analysis of
nascent RNA transcripts, we determined that the expression of these
hypertrophy-associated genes (the foetal gene programme), measured
at 24–48 h and elicited by a brief pulse of ET-1, was due to sustained
active transcription and not to carry over of transcripts from this initial
period of agonist exposure.
The persistent active transcription, in particular of c-Fos, a marker of
the IEG response, suggested that signalling from the ETA receptor was
also elevated for the duration of the time period studied. The temporal
proﬁle of ERK1/2 activation following ET-1 stimulation of NRVMs
described here and previously did not support this notion [15,16,18].
Consistent with previous studies, ERK1/2 phosphorylation is rapidly
increased within minutes and then diminishes to baseline 1 h post-
agonist stimulation [15]. This time course of signalling mediator
activation following GPCR stimulation is widely acknowledged and
contributes to avoiding toxicity [7,10]. To avoid persistent activation,
GPCRs and their downstream signalling cascades are conﬁgured for
regulation at multiple levels. In particular, GPCRs exhibit desensitisa-
tion through phosphorylation or endocytosis and signalling pathways
induce activity or expression of negative regulators [46,63]. Indeed, β2
adrenergic receptor signalling only lasts for minutes, with receptors
being inactivated by phosphorylation by β adrenergic receptor kinases
[64]. Downstream signalling pathways are also subject to strict regula-
tion. For example, the ERK1/2 cascade is regulated upstream through
modulation of MEK1 activity, and directly, by DUSP6 via dephosphor-
ylation at Thr202 and Tyr204 residues [65]. Knockout of DUSP6 results
in increased basal ERK1/2 signalling in the heart and protection against
pathology [57]. DUSP1 (also known as MAPK phosphatase 1, MKP1) is
rapidly upregulated in response to ET-1 in NRVMs [39] and when
overexpressed, inhibits ET-1 stimulated hypertrophic response [66].
Although signalling pathway activation peaks temporally proximal
to receptor engagement, results from experiments in which ERK1/2
were inhibited after this initial ERK activation period indicated that
signalling beyond this point was required to induce indices of hyper-
trophy measured at 24 h. These ﬁndings would indicate that despite
ERK1/2 activation peaking and then decaying to near baseline after 1 h
of agonist exposure, a remaining activity, indistinguishable from base-
Fig. 7. Inhibition of MEK1/2 with PD184352 attenuates the upregulation of hypertrophic markers induced by ET-1. Ai. Representative immunoblot for pERK1/2 and ERK1/2 in a total
cell lysate from NRVMs treated with ET-1 for 5, 10, 30, 60 min and 24 h. ii. Quantiﬁcation of pERK1/2 intensity relative to ERK1/2 in immunoblots as in (Ai) Each bar represents the
mean ± SEM (n = 3 primary cell preparations, *p < 0.05). B. Representative immunoblot for pERK1/2 and ERK1/2 following ET-1 application for 15 min ± PD184352. C. qRT-PCR
analysis of ANF mRNA abundance relative to the control upon stimulation with ET-1 ± PD. Assays were performed at 24 h. Each bar represents the mean ± SEM (n = 3 primary cell
preparations, *p < 0.05, **p < 0.01). D. 3H leucine incorporation assay of protein synthesis showing fold change relative to the control upon stimulation with ET-1 ± PD. Each bar
represents the mean ± SEM (n = 5 primary cell preparations, *p < 0.05, **p < 0.01). Statistical analysis was performed using a one-way ANOVA followed by post-hoc Holm-Sidak's
Multiple Comparison test (symbols above bars/plots).
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line at time points between 1 and 24 h, must be suﬃcient to generate
the hypertrophic response at up to 48 h. This description and dissection
of the window of signalling activity involved in activation of hyper-
trophic gene expression has not previously been reported, yet has been
considered likely important [22]. Given that our analysis of ERK1/2
activity was performed by immunoblotting of lysates prepared from cell
populations, dysynchronous low frequency oscillations in signalling
activity known to occur downstream of GPCR activation, would not be
detected.
The kinetics of signalling from ETA receptors appears more complex
than for other GPCRs, for example the α1 adrenergic receptor studied
here, which as previously shown is sensitive to antagonist application
after agonist [35]. Some of these properties of the ETA receptor may
depend upon the cell type/tissue in which the receptor is expressed.
Indeed, while ET receptors rapidly undergo ligand-induced desensitisa-
tion when overexpressed in Xenopus oocytes, they remain active for a
longer time courses in other systems. This is highlighted in the
vasculature where ETA- mediated elevation of [Ca2+]i in smooth
muscle cells is responsible for the prolonged vasoconstriction that
occurs subsequent to an initial ET-1 dependent vasodilation due to
signalling from the ETB receptor [67]. These chronic actions of ETA
receptor signalling reﬂect our observations in cardiac myocytes. While
Fig. 8. Overexpression of DN β-Arr1 in NRVMs potentiates the induction of ANF mRNA by transient ET-1 exposure and sensitises the response to antagonist. Ai. Representative
immunoblot for β-Arr1 in NRVMs infected with either GFP or DN β-Arr1 adenovirus. GAPDH is also shown as a loading control. ii. Quantiﬁcation of immunoblots for β-Arr1 intensity
relative to GAPDH intensity in GFP or DN β-Arr1 adenovirus infected NRVMs. Each bar represents the mean ± SEM (n = 3 primary cell preparations, *p < 0.05). B. Representative
confocal images of NRVMs infected with DN β-Arr1 adenovirus. GFP ﬂuorescence is shown in green, β-Arr1 immunostaining in red and nuclei in blue (DAPI). Scale bar represents 50 μm
C. qRT-PCR analysis of ANF mRNA abundance relative to the control upon stimulation with ET-1 ± BQ123 in NRVMs infected with GFP or DN β-Arr1 adenovirus. Assays were
performed at 24 h. Each bar represents the mean ± SEM (n = 3 primary cell preparations, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, NS; not signiﬁcant). D. qRT-PCR
analysis of ANF mRNA abundance relative to the control upon stimulation with ET-1 ± Dynole 34-2 in NRVMs. Assays were performed at 24 h. Each bar represents the mean ± SEM
(n = 3 primary cell preparations, *p < 0.05, **p < 0.01, ***p < 0.001, NS; not signiﬁcant) E. Model of the proposed pro-hypertrophic action of ET-1 and how the eﬀects of ET-1
exposure are sustained by ligand trapping by the receptor through endocytosis. The mechanism of Dynole 34-2 inhibition of endocytosis is also shown in the Cartoon. Statistical analysis
was performed using a one-way ANOVA followed by a post-hoc Holm-Sidak's Multiple Comparison test (symbols above bars/plots) or one-sample t-test.
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ETB receptors are expressed in cardiac myocytes [68], all of the eﬀects
of ET-1 observed in this study were sensitive to prior application of the
ETA receptor antagonist BQ123. Despite its high aﬃnity for the ETA
receptor [69] however, BQ123 did not aﬀect ET-1 receptor signalling
when applied subsequent to agonist. This inability of BQ123 to
antagonise the eﬀect of ET-1 may be due to the apparent irreversible
and ‘covalent’ binding of ET-1 to its receptor [50]. Alternatively, the
lack of an eﬀect of BQ123 can also arise through a mechanism in which
ligand bound ETA receptors internalise from the sarcolemma where
they are then insulated from extracellular BQ123 but continue to signal.
Indeed, imaging of GFP-tagged ETA receptors, monitoring of radio-
isotope labelled ET-1 and immunoﬂuorescent studies have revealed that
ET-1/ETA receptor complexes are internalised into caveolin-containing
vesicles within 10 min of ET-1 application [43,44]. Intriguingly,
following internalisation, the ET-1/ETA receptor complex continues to
signal providing a mechanism for this long lasting eﬀect of ET-1 [44]. In
contrast to other GPCRs, including the ETB receptor, ETA receptors are
not inactivated by phosphorylation thereby allowing persistent signal-
ling [51], although this feature of ETA receptor regulation is debated
[44]. The possibility for receptors to continue to signal following
clathrin-mediated endocytosis is not restricted to ETA receptors and
has described for the EGFR and also α1 adrenergic receptors and has
been termed ligand trapping [35]. However, the activity of intracellular
α1 adrenergic receptors after internalisation has been reported to be
inhibited by prazosin, which due to its hydrophilic properties is able to
access these intracellular receptors [35]. Recent studies have also
suggested the existence of intracellular ET receptors that respond to
‘intracrine’ ET-1 [58]. The mechanism by which this is brought about
remains to be fully established.
Receptor endocytosis often involves β-Arr recruitment to the active
receptor, which then initiates clathrin-mediated endocytosis. Here, we
found that expression of a DN β-Arr1 to prevent ETA receptor
endocytosis led to a potentiation of the eﬀect of ET-1 on ANF
expression. Moreover and perhaps surprisingly, this manoeuvre re-
sulted in the acquisition of sensitivity of the ET-1 stimulated increase in
indices of hypertrophy to BQ123. Together with similar observation
obtained using pharmacological inhibition of dynamin to inhibit
endocytosis, these data would suggest that β-Arr mediated internalisa-
tion underlies the mechanism that allows ET-1 signalling to persist.
Notably, the acquired ability of BQ123 to suppress the eﬀects of ET-1
when ETA receptors are forced to remain on the cell surface would also
suggest that interaction of ET-1 with its receptor is not irreversible. The
maintenance of high level transcription of markers of hypertrophy in
the face of endocytosis was surprising given that receptor endocytosis is
often a pathway for lysosomal degradation. As indicated above,
internalised ETA receptors can continue to signal [43], and have been
reported to be recycled to the plasma membrane via a pericentriolar
recycling compartment rather than directed to the lysosomes for
degradation [44,48].
While our results show continued signalling from ET-1/ETA recep-
tors for up to 48 h, our in vitro experimental model did not allow us to
probe longer-term eﬀects. Indeed, in animals, although initial makers of
hypertrophy are detectable within hours, hypertrophy endpoints devel-
op over a longer time course and future studies will explore how these
develop subsequent to transient hypertrophic stressors [20,22]. It is
clear however that, upon removal of a pro-hypertrophic stimulus, the
heart does not return to its pre-stimulated state for a number of days
suggesting some persistent signalling and long term eﬀects of ET-1 upon
cardiac physiology are also observed in vivo [58]. For example,
continuous perfusion of ET-1 via osmotic minipump results in a loss
of ET-1 induction of inotropy after 2 weeks [70]. How ET-1/ETA
receptor signalling is eventually inactivated remains to be determined
although ET-1 levels are rapidly cleared in vivo by ETB receptors [41].
Indeed, venous levels of ET-1 following infusion of the amount of ET-1
used in this study returns to baseline within 15 min [26]. ETA as well as
ETB receptors also desensitise via palmitoylation [71,72]. This mechan-
ism requires further study as it is unclear how this may aﬀect its role in
the initiation and termination of hypertrophic signalling [72].
Intriguingly, despite desensitisation and the persistent nature of the
ET-1 response, the ET-1 signalling system is ampliﬁed in cardiovascular
disease including in the cardiac myocyte compartment. Under stress
conditions such as stretch and β adrenergic stimulation in vitro, or
increased haemodynamic load in vivo, the expression of ET-1, the
endothelin converting enzyme (ECE) and ETA receptors is increased
[73]. This augmentation of the ET-1 pathway may thus serve to
maintain cellular sensitivity to ET-1 and to accommodate for the
eventual degradation of internalised receptors.
5. Conclusions and implications
ET-1 has been shown to drive progression of CVD and HF. Since the
discovery of ET-1 and its cognate receptors, there has been a focus on
identifying speciﬁc inhibitors for potential therapeutic use. However,
results of speciﬁc ETA receptor antagonists in clinical trials have been
disappointing [74]. As well as the high aﬃnity interaction between ET-
1 and ETA receptor, the multifaceted role of ET-1 in regulating the
cardiovascular system can make ET receptors an unpredictable ther-
apeutic target [75]. Lack of eﬃcacy of antagonists upon the ETA
receptor may in part be explained by the continued signalling of ET
receptors from the intracellular space. Our ﬁndings that inhibitors of
endocytosis render ETA receptors sensitive to antagonists may provide
an avenue for improved therapy at this receptor. There is currently a
limited understanding of ET-1/ETA receptor interaction during the
induction of cardiac hypertrophy. The ﬁnding that ET-1/ETA receptor
signalling persists in NRVMs and in vivo has important implications for
the mechanisms underlying the prolonged duration of ET-1-induced
hypertrophic gene transcription. It is clear from these data that active
transcription is maintained even following removal of a stimulus. In the
in vivo situation, the persistence of hypertrophic transcription would
serve to maintain the pathological remodelling of the heart in the
absence of continued stimulus. Indeed, in vivo debanding models have
revealed that hypertrophy can take up to 4–8 weeks to reverse
following removal of the pressure overload [76–78]. Further study of
ETA receptor pharmacology, the dynamics of intracellular signalling
pathways and desensitisation mechanisms are thus required to gain
insight into how this receptor can be targeted for therapeutic beneﬁt.
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